Genmab — Marts 2015
-
Mere godt nyt til Ofatumumab aficionados. To nye studier i Nefrotisk syndrom hos børn.
-
- Behandlingsresistent Nefrotisk syndrom, placebokontrolleret, n=50, https://clinicaltrials.gov/ct2/show/NCT02394106?term=ofatumumab&rank=26
-
- Behandlingsafhængig Nefrotisk syndrom, Head to head mod Rituximab, n=140, https://clinicaltrials.gov/ct2/show/NCT02394119?term=ofatumumab&rank=54
-
Gad vide om den nyvundne aktivitet har noget med skiftet til Novartis at gøre?
-
GILD med lidt modgang http://finance.yahoo.com/news/gilead-warns-hepatitis-patient-heart-183620670.html
-
Gode tanker celsius.

-
-
Angående Novartis´ overtagelse af GSK cancer divisionen, så er Arzerra jo kun en lille del af denne, men det bliver spændende når vi en gang ser nogle udmeldinger fra Novartis omkring planerne for Arzerra ! Tror dog ikke vi skal forvente det vilde i år.
-
Apropos de nye studier med ofatumumab http://www.nejm.org/doi/full/10.1056/NEJMc1308488
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind